| 摘要 |
Disclosed is a combination which comprises (a) N-{5- benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2- pyrimidine- amine and (b) a chemotherapeutic agent selected from antineoplastic agents selected from the group consisting of aromatase inhibitors, antiestrogens, topomerase I inhibitors, topomerase II inhibitors selected from the group consisting of epirubicin, idarubicin, nemorubicin, the anthraquinones mitoxonatrone and losoxantrone and teniposide, microtubule active agents selected from the group consisting of docetaxel, vinblastine, vinorelbine and discodermolide, alkylating agents selected from the group consisting of ifosfamide andmelphalan, antineoplastic antimetabolites selected from the group consisting of capecitabine, gemcitabine and edatrexate, platin compounds and compounds decreasing the protein kinase activity and further anti-angiogenic compounds selected from the group consisting of compounds decreasing the activity of the vascular endothelial growth factor (VEGF), of the platelet derived growth factor (PDGF) and protein kinase and of protein kinase C and antiangiogenic compounds having another mechanism for their activity, gonadrolin agonists, anti-androgens, bisphosphonates and trastuzumab and agents effective in treating acute or chronic transplant rejection, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
|
